Proteome Sciences PLC (PRM) - Total Liabilities
Based on the latest financial reports, Proteome Sciences PLC (PRM) has total liabilities worth GBX17.79 Million GBX (≈ $2.16K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Proteome Sciences PLC (PRM) equity growth momentum to track the company's year-over-year net asset growth rate.
Proteome Sciences PLC - Total Liabilities Trend (1994–2025)
This chart illustrates how Proteome Sciences PLC's total liabilities have evolved over time, based on quarterly financial data. See PRM free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Proteome Sciences PLC Competitors by Total Liabilities
The table below lists competitors of Proteome Sciences PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bay Capital PLC
LSE:BAY
|
UK | GBX91.67K |
|
Sentia Asa
OL:SNTIA
|
Norway | Nkr4.96 Billion |
|
SEEEN PLC
LSE:SEEN
|
UK | GBX1.24 Million |
|
Eneraqua Technologies PLC
LSE:ETP
|
UK | GBX23.55 Million |
|
The Siam Cement Public Company Limited
F:TCM1
|
Germany | €424.75 Billion |
|
Petards Group plc
LSE:PEG
|
UK | GBX6.58 Million |
|
Delta Electronics (Thailand) Public Company Limited
F:DLS
|
Germany | €67.70 Billion |
Liability Composition Analysis (1994–2025)
This chart breaks down Proteome Sciences PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Proteome Sciences PLC (PRM) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Proteome Sciences PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Proteome Sciences PLC (1994–2025)
The table below shows the annual total liabilities of Proteome Sciences PLC from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | GBX17.79 Million ≈ $2.16K |
+13.12% |
| 2024-12-31 | GBX15.72 Million ≈ $1.91K |
+8.26% |
| 2023-12-31 | GBX14.52 Million ≈ $1.77K |
-100.00% |
| 2022-12-31 | GBX1.44 Trillion ≈ $175.75 Million |
+9.91% |
| 2021-12-31 | GBX1.31 Trillion ≈ $159.91 Million |
+2.46% |
| 2020-12-31 | GBX1.28 Trillion ≈ $156.06 Million |
+19.36% |
| 2019-12-31 | GBX1.07 Trillion ≈ $130.74 Million |
+0.47% |
| 2018-12-31 | GBX1.07 Trillion ≈ $130.13 Million |
+0.21% |
| 2017-12-31 | GBX1.07 Trillion ≈ $129.85 Million |
+796.27% |
| 2016-12-31 | GBX119.08 Billion ≈ $14.49 Million |
-88.70% |
| 2015-12-31 | GBX1.05 Trillion ≈ $128.26 Million |
-18.41% |
| 2014-12-31 | GBX1.29 Trillion ≈ $157.19 Million |
+0.96% |
| 2013-12-31 | GBX1.28 Trillion ≈ $155.70 Million |
+16583717.49% |
| 2012-12-31 | GBX7.72 Million ≈ $938.87 |
+1.40% |
| 2011-12-31 | GBX7.61 Million ≈ $925.92 |
-9.17% |
| 2010-12-31 | GBX8.38 Million ≈ $1.02K |
-45.73% |
| 2009-12-31 | GBX15.44 Million ≈ $1.88K |
+27.95% |
| 2008-12-31 | GBX12.07 Million ≈ $1.47K |
+37.14% |
| 2007-12-31 | GBX8.80 Million ≈ $1.07K |
+131.04% |
| 2006-12-31 | GBX3.81 Million ≈ $463.32 |
+120.88% |
| 2005-12-31 | GBX1.72 Million ≈ $209.76 |
+12.03% |
| 2004-12-31 | GBX1.54 Million ≈ $187.24 |
-40.43% |
| 2003-12-31 | GBX2.58 Million ≈ $314.31 |
+30.20% |
| 2002-12-31 | GBX1.98 Million ≈ $241.41 |
+60.27% |
| 2001-12-31 | GBX1.24 Million ≈ $150.63 |
-21.40% |
| 2000-12-31 | GBX1.57 Million ≈ $191.63 |
+125.97% |
| 1999-12-31 | GBX697.00K ≈ $84.80 |
-19.14% |
| 1998-12-31 | GBX862.00K ≈ $104.88 |
+56.44% |
| 1997-12-31 | GBX551.00K ≈ $67.04 |
+93.33% |
| 1996-12-31 | GBX285.00K ≈ $34.68 |
-40.63% |
| 1995-12-31 | GBX480.00K ≈ $58.40 |
-30.23% |
| 1994-12-31 | GBX688.00K ≈ $83.71 |
0.00% |
| 1994-10-31 | GBX688.00K ≈ $83.71 |
-- |
About Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in pla… Read more